|
|
Prof Malcolm Mason discusses the results of an intergroup study - carried out by the UK Medical Research Council (MRC), the National Cancer Institute of Canada (NCIC) and the Southwest Oncology Group (SWOG) from the United States - looking at patients with locally advanced prostate cancer or high risk localised prostate cancer who would normally be treated with androgen deprivation therapy (ADT). This trial compared ADT alone with ADT plus radiotherapy and conclusively demonstrated the benefit of adding radiotherapy to ADT. Prof Mason speaks about the level of side effects experienced by the patients and looks forward to the results of the ongoing NCRI CHHIP study into hypofractionated radiotherapy.
|
|
Video Length: 0
Date Found: January 11, 2011
Date Produced:
|
|
 www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
 www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
 www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
 www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
 www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|